lerapolturev
istari
['melanoma', 'istari onco']
istari oncology announces presentation of clinical responses from luminos- 102, an ongoing phase 2 trial of lerapolturev in anti-pd-1 refractory metastatic melanoma at the society for melanoma research (smr) 2022 congress 
Pharmaceutical News - Direct Information